LENZ Therapeutics, Inc.
LENZ evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for LENZ—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LENZ
LENZ Therapeutics is a pre-commercial biopharmaceutical company developing LNZ100, a once-daily eye drop for presbyopia, with a completed Phase 3 program and an FDA decision pending.
Key risk: FDA approval uncertainty
BioSniper Score
Based on 6 of 6 signals
Market Cap
$160.6M
Cash Runway
6.7 moLead Asset
lnz100 (Phase 3)
Next Catalyst
Patent_Expiry · Mar 15, 2044Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 4 clinical trials · 1 catalyst · 1 FDA decision for LENZ Therapeutics, Inc..
Similar companies
LENZ Therapeutics is a pre-commercial biopharmaceutical company developing LNZ100, a once-daily eye drop for presbyopia, with a completed Phase 3 program and an FDA decision pending.
- LENZ has completed Phase 3 CLARITY trials for LNZ100, a once-daily eye drop for presbyopia, with clinical activities substantially wound down as of March 2024 [sec_mda · as of 2025-07-30].
- As of June 30, 2025, the company reported cash & equivalents of $24.2M, total revenue of $5.5M, and a net loss of -$31.9M [sec].
- The company has incurred net losses each year since inception, with an accumulated deficit of $174.5M as of June 30, 2025 [sec_mda · as of 2025-07-30].
- LENZ expects to continue building commercial infrastructure for LNZ100, subject to FDA approval, and believes existing cash will fund operations to positive cash flow post-launch [sec_mda · as of 2025-05-07].
- The company has no revenue from product sales and will not generate such revenue unless regulatory approval for LNZ100 is obtained [sec_mda · as of 2025-05-07].
What works
- LENZ has completed its Phase 3 CLARITY trials, reducing clinical research expenses and allowing focus on pre-commercial activities [sec_mda · as of 2025-07-30].
- The company has built a cash position that management believes will fund the company to positive operating cash flow after a potential commercial launch of LNZ100 [sec_mda · as of 2025-05-07].
- LENZ has invested in pre-commercial marketing, sales infrastructure, and manufacturing to support a potential launch of LNZ100 [sec_mda · as of 2025-07-30].
What to weigh
- LENZ is a pre-commercial company with no product revenue and a history of net losses, with an accumulated deficit of $174.5M as of June 30, 2025 [sec_mda · as of 2025-07-30].
- The company's future depends entirely on FDA approval and successful commercialization of LNZ100, with no other pipeline candidates mentioned [sec_mda · as of 2025-05-07].
- Cash and equivalents have declined from $194.1M as of March 31, 2025 to $24.2M as of June 30, 2025, reflecting significant spending on pre-commercial activities [sec_mda · as of 2025-05-07] [sec].
From the filings
Quoted directly from source documents.
LENZ has completed Phase 3 CLARITY trials and wound down clinical activities.
“reduced clinical research expenses related to the substantial completion of our Phase 3 CLARITY trials in March 2024”
SEC MD&A · July 30, 2025
LENZ has an accumulated deficit of $174.5M as of June 30, 2025.
“as of June 30, 2025, we had an accumulated deficit of $174.5 million”
SEC MD&A · July 30, 2025
LENZ expects to fund operations to positive cash flow after commercial launch.
“will allow us to continue to build infrastructure and commercialize LNZ100, subject to FDA approval, and will be sufficient to fund the Company to positive operating cash flow subsequent to such commercial launch”
SEC MD&A · May 7, 2025
LENZ has no product revenue and depends on FDA approval.
“We do not expect to generate any revenue from product sales unless and until we successfully obtain regulatory approval for LNZ100”
SEC MD&A · May 7, 2025
Catalyst timeline
- 2044-03-15 · Patent_Expiry · VIZZ — Patent/Exclusivity Expiry: VIZZ — Patent or exclusivity expiry for VIZZ, which may affect long-term competitive positioning.
Risks & what to watch (3)›
Key risks
- FDA approval uncertainty — LENZ's sole product candidate LNZ100 requires FDA approval; failure would eliminate revenue prospects [sec_mda · as of 2025-05-07].
- Cash burn and runway — Cash declined from $194.1M (Mar 2025) to $24.2M (Jun 2025); ongoing losses may require additional financing [sec] [sec_mda · as of 2025-05-07].
- Pre-commercial stage risk — Company has no history of product sales, marketing, or manufacturing at scale [sec_mda · as of 2025-05-07].
What to watch
- FDA decision on LNZ100 for presbyopia, which will determine the company's ability to generate revenue [sec_mda · as of 2025-05-07].
- Cash burn rate and potential need for additional financing given the decline from $194.1M to $24.2M in three months [sec] [sec_mda · as of 2025-05-07].
- Commercial launch execution, including manufacturing scale-up and sales infrastructure build-out [sec_mda · as of 2025-07-30].
Sources: SEC filings · SEC MD&A · Generated August 17, 2026 · How we verify sources →
Run LENZ Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available LENZ Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
6.7 months
D/E 0.08 · 0% dilution
Lead: Approved
3 candidates
1 upcoming, next in ~6407d
3 buys · 0 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
141
Total value held
$222.7M
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 4,178,823 | $38.2M |
| fmr llc | 3,597,784 | $32.9M |
| vanguard capital management llc | 2,082,376 | $19.1M |
| blackrock, inc. | 1,976,823 | $18.1M |
| franklin resources inc | 1,100,148 | $10.1M |
| millennium management llc | 869,257 | $8.0M |
| eversource wealth advisors, llc | 24,547 | $6.7M |
| morgan stanley | 648,848 | $5.9M |
| bank of america corp /de/ | 547,534 | $5.0M |
| geode capital management, llc | 524,574 | $4.8M |
Showing top 10 of 141 institutional holders of LENZ Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 49.5%
- Days to cover
- 7.8
- Shares short
- 9,033,400
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
LENZ short interestGovernance
Frequently asked questions
What is the AI investment thesis for LENZ Therapeutics, Inc.?
LENZ Therapeutics is a pre-commercial biopharmaceutical company developing LNZ100, a once-daily eye drop for presbyopia, with a completed Phase 3 program and an FDA decision pending.
What is LENZ Therapeutics, Inc.'s lead drug candidate?
LENZ Therapeutics, Inc.'s most advanced tracked candidate is lnz100 (Phase 3) for presbyopia.
What is LENZ Therapeutics, Inc.'s next catalyst?
LENZ Therapeutics, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: VIZZ" — expected March 15, 2044.
Who is the CEO of LENZ Therapeutics, Inc.?
Mr. Evert B. Schimmelpennink is the chief executive officer of LENZ Therapeutics, Inc. (LENZ).
Where is LENZ Therapeutics, Inc. headquartered?
LENZ Therapeutics, Inc. (LENZ) is headquartered in Solana Beach, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.